Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.40 |
| ▸ | HSD11B1 | P28845 | 6/20 | 0.39 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | BRD2 | P25440 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | EPHX2 | P34913 | 3/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | CNR2 | P34972 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 2/20 | 0.32 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4500488 | 0.94 | MEN1 (0.44) | MEN1KMT2APKMADORA3HSD11B1 | |
| SCHEMBL4518124 | 0.92 | MEN1 (0.42) | MEN1KMT2APKMADORA3HSD11B1 | |
| SCHEMBL1896319 | 0.88 | MEN1 (0.40) | MEN1KMT2APKMADORA3HSD11B1 | |
| SCHEMBL4511612 | 0.78 | KMT2A (0.44) | MEN1KMT2APKMHSD11B1LMNA | |
| SCHEMBL9068591 | 0.75 | MEN1 (0.36) | MEN1KMT2APKMADORA3HSD11B1 | |
| SCHEMBL1397765 | 0.74 | MEN1 (0.33) | MEN1KMT2APKM | |
| SCHEMBL4501285 | 0.74 | ALDH1A1 (0.38) | MEN1KMT2ALMNAALDH1A1L3MBTL1 | |
| SCHEMBL23538864 | 0.72 | BRD4 (0.39) | MEN1KMT2APKMBRD4BRD2 | |
| SCHEMBL2162510 | 0.71 | MEN1 (0.31) | MEN1KMT2APKMLMNAALDH1A1 | |
| SCHEMBL19271807 | 0.71 | ALDH1A1 (0.39) | MEN1KMT2APKMBRD4BRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 79 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | Ananda Scientific, Inc. (US) | 2025-06-19 | — | — | US | disclosed |
| US-11607407-B2 | Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use | RELMADA THERAPEUTICS, INC. (US) | 2023-03-21 | — | — | US | disclosed |
| CN-107115326-B | Skin pharmaceutical composition of 1-methyl-N- (2, 6-xylyl) -2-piperidine formamide and using method thereof | 雷尔玛达治疗股份有限公司 | 2021-01-22 | — | — | CN | disclosed |
| EP-2557924-B1 | DERMAL PHARMACEUTICAL COMPOSITIONS OF 1-METHYL-2',6'-PIPECOLOXYLIDIDE AND METHOD OF USE | RELMADA THERAPEUTICS INC (US) | 2019-06-12 | — | — | EP | disclosed |
| US-20170333410-A1 | Dermal Pharmaceutical Compositions of 1-Methyl-2',6'-Pipecoloxylidide and Method of Use | RELMADA THERAPEUTICS, INC. (US) | 2017-11-23 | — | — | US | disclosed |
| CN-107115326-A | The dennophannaceutical compositions and its application method of 1 methyl N (2,6 xylyl) 2 piperidine formamides | 雷尔玛达治疗股份有限公司 | 2017-09-01 | — | — | CN | disclosed |
| CN-103491778-B | Skin pharmaceutical composition of 1-methyl-N- (2, 6-xylyl) -2-piperidine formamide and using method thereof | 雷尔玛达治疗股份有限公司 | 2017-05-31 | — | — | CN | disclosed |
| EP-2029579-B1 | CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | LILLY CO ELI (US) | 2014-12-31 | — | — | EP | disclosed |
| EP-2125750-B1 | CYCLIC UREA AND CARBAMATE INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE 1 | VITAE PHARMACEUTICALS INC (US) | 2014-05-21 | — | — | EP | disclosed |
| CN-103491778-A | Skin pharmaceutical composition of 1-methyl-N- (2, 6-xylyl) -2-piperidine formamide and using method thereof | REIMADA THERAPEUTICS INC | 2014-01-01 | — | — | CN | disclosed |
| WO-2007124329-A1 | CYCLOHEXYLIMIDAZOLE LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-01 | — | — | WO | disclosed |
| WO-2007124254-A2 | CYCLOHEXYLPYRAZOLE-LACTAM DERIVATIVES AS INHIBITORS OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE 1 | ELI LILLY AND COMPANY (US) | 2007-11-01 | — | — | WO | disclosed |
| CN-1980889-A | Adamantyl pyrrolidin-2-one derivatives as inhibitors of 11-beta hydroxysteroid dehydrogenase | JANSSEN PHARMACEUTICA NV (BE) | 2007-06-13 | — | — | CN | disclosed |
| EP-1747198-A1 | ADAMANTYL PYRROLIDIN-2-ONE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-31 | — | — | EP | disclosed |
| EP-1747198-A1 | ADAMANTYL PYRROLIDIN-2-ONE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005108361-A1 | ADAMANTYL PYRROLIDIN-2-ONE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-17 | — | — | WO | disclosed |
| WO-2005108361-A1 | ADAMANTYL PYRROLIDIN-2-ONE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2005-11-17 | — | — | WO | disclosed |
| US-6887646-B1 | Chemical amplification resist composition | MITSUBISHI RAYON CO., LTD. (JP) | 2005-05-03 | — | — | US | disclosed |
| EP-1209525-A1 | CHEMICAL AMPLIFICATION RESIST COMPOSITION | Mitsubishi Rayon Co., Ltd. (JP) | 2002-05-29 | — | — | EP | disclosed |
| EP-0668290-B1 | Physiologically active substance well capable of permeating biomembrane | TEIKOKU SEIYAKU KK (JP) | 1998-11-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170333410-A1 | Dermal Pharmaceutical Compositions of 1-Methyl-2',6'-Pipecoloxylidide and Method of Use | PIP4K2C, PIP5K1C, PIP4K2A | MEN1 2421/4885KMT2A 1828/4885PKM 4224/4885 |
| US-11607407-B2 | Dermal pharmaceutical compositions of 1-methyl-2′,6′-pipecoloxylidide and method of use | PIP4K2C, PIP5K1C, PIP4K2A | MEN1 2575/4885KMT2A 1862/4885PKM 4230/4885 |
| US-20250195409-A1 | METHODS FOR IMPROVING CUTANEOUS PERMEATION OF CANNABINOIDS AND FATTY ACID AMIDES | CNR2, CNR1, FAAH | MEN1 4840/4885KMT2A 2718/4885PKM 3834/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.